Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Vernalis PLC: Year-End Trading Update and Notice of Full Year Results
-
Vernalis PLC: FDA Issues a Complete Response Letter on CCP-07 NDA
-
Vernalis PLC: Unaudited Interim Results for the six months ended 31 December 2016
-
Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc
-
Vernalis PLC: Notice of Results for Six Months Ended 31/12/2016
-
Vernalis PLC: FDA accepts CCP-08 NDA for full review
-
Vernalis plc: AGM Statement
-
Vernalis PLC Announces Results Announcement for the 12 Months Ended 30 June 2016
-
Vernalis Achieves a Milestone in Its Oncology Collaboration With Servier
-
Vernalis Notes the Acquisition of RedoxTherapies by Juno Therapeutics
-
Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
-
Year-End Trading Update and Notice of Results
-
Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
-
Vernalis Announce CCP-08 Single-Dose Study Results
-
Vernalis plc Announces Unaudited Interim Results Announcement for the Six Months Ended 31 December 2015
-
Vernalis plc ("Vernalis" or the "Company") Notice of Results for the Six Months Ended 31 December 2015
-
Vernalis Announces Corvus Pharmaceuticals, Inc. as Its Worldwide Licensee for Their Adenosine Antagonist Program
-
Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
-
Vernalis plc ("Vernalis" or the "Company") AGM Statement
-
Vernalis Announces Start of CCP-08 12 Month Stability Testing
-
Vernalis PLC: Results announcement for 18 months ended 30/06/15
-
Vernalis PLC Launches Tuzistra(TM) XR (Codeine Polistirex and Chlorpheniramine Polistirex) for Cough Relief With 12-Hour Dosing
-
Vernalis plc - Appointment of Non-Executive Director
-
Vernalis plc - Appointment of Non-Executive Director
-
Vernalis Announces CCP-07 Starts 12 Month Stability Testing
-
Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex)
-
Vernalis plc Enters Into Research Collaboration With Taisho Pharmaceutical Co., Ltd
-
Vernalis and Asahi Kasei Pharma Achieve Research Milestone